cloudfront

Report Detail



Pharma & HealthcareGlobal Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • RnM2414260
  • |
  • 14 September, 2018
  • |
  • Global
  • |
  • 100 pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Table of Contents

    1 Market Overview

    • 1.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Introduction
    • 1.2 Market Analysis by Type
    • 1.2.1 Corticosteroids
  • 1.2.2 Intravenous Immunoglobulin (IVIG)
  • 1.2.3 Anti-D Immunoglobulin
  • 1.2.4 Thrombopoietin Receptor Agonists (TPO-RA)
  • 1.2.5 Others
  • 1.3 Market Analysis by Applications
  • 1.3.1 Hospitals
  • 1.3.2 Clincs
  • 1.3.3 Others
  • 1.4 Market Analysis by Regions
  • 1.4.1 North America (United States, Canada and Mexico)
  • 1.4.1.1 United States Market States and Outlook (2013-2023)
  • 1.4.1.2 Canada Market States and Outlook (2013-2023)
  • 1.4.1.3 Mexico Market States and Outlook (2013-2023)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
  • 1.4.2.1 Germany Market States and Outlook (2013-2023)
  • 1.4.2.2 France Market States and Outlook (2013-2023)
  • 1.4.2.3 UK Market States and Outlook (2013-2023)
  • 1.4.2.4 Russia Market States and Outlook (2013-2023)
  • 1.4.2.5 Italy Market States and Outlook (2013-2023)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  • 1.4.3.1 China Market States and Outlook (2013-2023)
  • 1.4.3.2 Japan Market States and Outlook (2013-2023)
  • 1.4.3.3 Korea Market States and Outlook (2013-2023)
  • 1.4.3.4 India Market States and Outlook (2013-2023)
  • 1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
  • 1.4.4 South America, Middle East and Africa
  • 1.4.4.1 Brazil Market States and Outlook (2013-2023)
  • 1.4.4.2 Egypt Market States and Outlook (2013-2023)
  • 1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
  • 1.4.4.4 South Africa Market States and Outlook (2013-2023)
  • 1.4.4.5 Nigeria Market States and Outlook (2013-2023)
  • 1.5 Market Dynamics
  • 1.5.1 Market Opportunities
  • 1.5.2 Market Risk
  • 1.5.3 Market Driving Force
  • 2 Manufacturers Profiles

    • 2.1 Roch
    • 2.1.1 Business Overview
  • 2.1.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Type and Applications
  • 2.1.2.1 Product A
  • 2.1.2.2 Product B
  • 2.1.3 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.2 Amgen Inc
  • 2.2.1 Business Overview
  • 2.2.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Type and Applications
  • 2.2.2.1 Product A
  • 2.2.2.2 Product B
  • 2.2.3 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.3 Grifols Biologicals Inc.
  • 2.3.1 Business Overview
  • 2.3.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Type and Applications
  • 2.3.2.1 Product A
  • 2.3.2.2 Product B
  • 2.3.3 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 2.4 GlaxoSmithKline Plc
  • 2.4.1 Business Overview
  • 2.4.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Type and Applications
  • 2.4.2.1 Product A
  • 2.4.2.2 Product B
  • 2.4.3 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
  • 3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

    • 3.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Market Share by Manufacturer (2016-2017)
    • 3.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Market Share by Manufacturer (2016-2017)
    • 3.3 Market Concentration Rate
    • 3.3.1 Top 3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Manufacturer Market Share in 2017
  • 3.3.2 Top 6 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Manufacturer Market Share in 2017
  • 3.4 Market Competition Trend
  • 4 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Analysis by Regions

    • 4.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Market Share by Regions
    • 4.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Market Share by Regions (2013-2018)
  • 4.1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Market Share by Regions (2013-2018)
  • 4.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 4.3 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 4.4 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 4.5 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 4.6 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 5 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Countries

    • 5.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Market Share by Countries
    • 5.1.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Market Share by Countries (2013-2018)
  • 5.1.2 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Market Share by Countries (2013-2018)
  • 5.2 United States Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 5.3 Canada Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 5.4 Mexico Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 6 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Countries

    • 6.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Market Share by Countries
    • 6.1.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Market Share by Countries (2013-2018)
  • 6.1.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Market Share by Countries (2013-2018)
  • 6.2 Germany Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 6.3 UK Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 6.4 France Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 6.5 Russia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 6.6 Italy Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 7 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Countries

    • 7.1 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Market Share by Countries
    • 7.1.1 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Market Share by Countries (2013-2018)
  • 7.1.2 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Market Share by Countries (2013-2018)
  • 7.2 China Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 7.3 Japan Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 7.4 Korea Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 7.5 India Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 7.6 Southeast Asia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 8 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Countries

    • 8.1 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Market Share by Countries
    • 8.1.1 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Market Share by Countries (2013-2018)
  • 8.1.2 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Market Share by Countries (2013-2018)
  • 8.2 Brazil Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 8.3 Argentina Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 8.4 Colombia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 9 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics by Countries

    • 9.1 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Market Share by Countries
    • 9.1.1 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Market Share by Countries (2013-2018)
  • 9.1.2 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Market Share by Countries (2013-2018)
  • 9.2 Saudi Arabia Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 9.3 UAE Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 9.4 Egypt Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 9.5 Nigeria Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 9.6 South Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Growth Rate (2013-2018)
  • 10 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Segment by Type

    • 10.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Market Share by Type (2013-2018)
    • 10.1.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales and Market Share by Type (2013-2018)
  • 10.1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue and Market Share by Type (2013-2018)
  • 10.2 Corticosteroids Sales Growth and Price
  • 10.2.1 Global Corticosteroids Sales Growth (2013-2018)
  • 10.2.2 Global Corticosteroids Price (2013-2018)
  • 10.3 Intravenous Immunoglobulin (IVIG) Sales Growth and Price
  • 10.3.1 Global Intravenous Immunoglobulin (IVIG) Sales Growth (2013-2018)
  • 10.3.2 Global Intravenous Immunoglobulin (IVIG) Price (2013-2018)
  • 10.4 Anti-D Immunoglobulin Sales Growth and Price
  • 10.4.1 Global Anti-D Immunoglobulin Sales Growth (2013-2018)
  • 10.4.2 Global Anti-D Immunoglobulin Price (2013-2018)
  • 10.5 Thrombopoietin Receptor Agonists (TPO-RA) Sales Growth and Price
  • 10.5.1 Global Thrombopoietin Receptor Agonists (TPO-RA) Sales Growth (2013-2018)
  • 10.5.2 Global Thrombopoietin Receptor Agonists (TPO-RA) Price (2013-2018)
  • 10.6 Others Sales Growth and Price
  • 10.6.1 Global Others Sales Growth (2013-2018)
  • 10.6.2 Global Others Price (2013-2018)
  • 11 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Segment by Application

    • 11.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Market Share by Application (2013-2018)
    • 11.2 Hospitals Sales Growth (2013-2018)
    • 11.3 Clincs Sales Growth (2013-2018)
    • 11.4 Others Sales Growth (2013-2018)

    12 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast (2018-2023)

    • 12.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales, Revenue and Growth Rate (2018-2023)
    • 12.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast by Regions (2018-2023)
    • 12.2.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast (2018-2023)
  • 12.2.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast (2018-2023)
  • 12.2.3 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast (2018-2023)
  • 12.2.4 South America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast (2018-2023)
  • 12.2.5 Middle East and Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast (2018-2023)
  • 12.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast by Type (2018-2023)
  • 12.3.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Type (2018-2023)
  • 12.3.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share Forecast by Type (2018-2023)
  • 12.4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Forecast by Application (2018-2023)
  • 12.4.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Sales Forecast by Application (2018-2023)
  • 12.4.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Share Forecast by Application (2018-2023)
  • 13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
    • 13.1.1 Direct Marketing
  • 13.1.2 Indirect Marketing
  • 13.1.3 Marketing Channel Future Trend
  • 13.2 Distributors, Traders and Dealers
  • 14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      ITP (idiopathic thrombocytopenic purpura) is a rare disease with low affliction rates. This disease leads to excessive bruising or bleeding due to the lack of blood platelets. It is also known as immune thrombocytopenia and can affect children and adults alike.

      Scope of the Report:

      This report focuses on the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

      Increasing demand for combination therapies therapy is expected to fuel the future growth of the ITP therapeutics market. Clinical evidence suggest that combination therapies entail relatively lower side effects, are cost effective and display higher response rates in patients.

      The worldwide market for Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.

      Market Segment by Manufacturers, this report covers

      Roch

      Amgen Inc

      Grifols Biologicals Inc.

      GlaxoSmithKline Plc

      Market Segment by Regions, regional analysis covers

      North America (United States, Canada and Mexico)

      Europe (Germany, France, UK, Russia and Italy)

      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

      South America (Brazil, Argentina, Colombia etc.)

      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers

      Corticosteroids

      Intravenous Immunoglobulin (IVIG)

      Anti-D Immunoglobulin

      Thrombopoietin Receptor Agonists (TPO-RA)

      Others

      Market Segment by Applications, can be divided into

      Hospitals

      Clincs

      Others

      There are 15 Chapters to deeply display the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market.

      Chapter 1, to describe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;

      Chapter 2, to analyze the top manufacturers of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics, with sales, revenue, and price of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics, in 2016 and 2017;

      Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

      Chapter 4, to show the global market by regions, with sales, revenue and market share of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics, for each region, from 2013 to 2018;

      Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

      Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

      Chapter 12, Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

      Chapter 13, 14 and 15, to describe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source




      Summary:
      Get latest Market Research Reports on Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics . Industry analysis & Market Report on Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics is a syndicated market report, published as Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,480.00
      $5,220.00
      $6,960.00
      2,336.82
      3,505.23
      4,673.64
      3,202.30
      4,803.44
      6,404.59
      421,567.20
      632,350.80
      843,134.40
      230,770.63
      346,155.95
      461,541.26
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report